Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 May;76(5):650–655. doi: 10.1136/jnnp.2004.047993

Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study

C Kipps 1, A Duggins 1, N Mahant 1, L Gomes 1, J Ashburner 1, E McCusker 1
PMCID: PMC1739615  PMID: 15834021

Abstract

Background and objectives: Regional cerebral atrophy occurs in carriers of the Huntington's disease (HD) gene mutation before clinical diagnosis is possible. The current inability to reliably measure progression of pathology in this preclinical phase impedes development of therapies to delay clinical onset. We hypothesised that longitudinal statistical imaging would detect progression of structural pathology in preclinical carriers of the HD gene mutation, in the absence of measurable clinical change.

Methods: Thirty subjects (17 preclinical mutation positive, 13 mutation negative) underwent serial clinical and magnetic resonance imaging (MRI) assessments over an interval of 2 years. Statistically significant changes in regional grey and white matter volume on MRI were analysed using tensor based morphometry (TBM). This technique derives a voxel-wise estimation of regional tissue volume change from the deformation field required to warp a subject's early to late T1 images.

Results: Over 2 years, there was progressive regional grey matter atrophy in mutation-positive relative to negative subjects, without significant clinical progression of disease. Significant grey matter volume loss was limited to bilateral putamen and globus pallidus externa (GPe), left caudate nucleus, and left ventral midbrain in the region of the substantia nigra.

Conclusions: While these results are consistent with previous cross sectional pathologic and morphometric studies, significant progression of atrophy in HD before the onset of significant clinical decline is now demonstrable with longitudinal statistical imaging. Such measures could be used to assess the efficacy of potential disease modifying drugs in slowing the progression of pathology before confirmed clinical onset of HD.

Full Text

The Full Text of this article is available as a PDF (190.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albin R. L., Reiner A., Anderson K. D., Dure L. S., 4th, Handelin B., Balfour R., Whetsell W. O., Jr, Penney J. B., Young A. B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 1992 Apr;31(4):425–430. doi: 10.1002/ana.410310412. [DOI] [PubMed] [Google Scholar]
  2. Albin R. L. Selective neurodegeneration in Huntington's disease. Ann Neurol. 1995 Dec;38(6):835–836. doi: 10.1002/ana.410380602. [DOI] [PubMed] [Google Scholar]
  3. Ashburner J., Andersson J. L., Friston K. J. Image registration using a symmetric prior--in three dimensions. Hum Brain Mapp. 2000 Apr;9(4):212–225. doi: 10.1002/(SICI)1097-0193(200004)9:4<212::AID-HBM3>3.0.CO;2-#. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ashburner J., Friston K. J. Voxel-based morphometry--the methods. Neuroimage. 2000 Jun;11(6 Pt 1):805–821. doi: 10.1006/nimg.2000.0582. [DOI] [PubMed] [Google Scholar]
  5. Aylward E. H., Anderson N. B., Bylsma F. W., Wagster M. V., Barta P. E., Sherr M., Feeney J., Davis A., Rosenblatt A., Pearlson G. D. Frontal lobe volume in patients with Huntington's disease. Neurology. 1998 Jan;50(1):252–258. doi: 10.1212/wnl.50.1.252. [DOI] [PubMed] [Google Scholar]
  6. Aylward E. H., Brandt J., Codori A. M., Mangus R. S., Barta P. E., Harris G. J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology. 1994 May;44(5):823–828. doi: 10.1212/wnl.44.5.823. [DOI] [PubMed] [Google Scholar]
  7. Aylward E. H., Codori A. M., Barta P. E., Pearlson G. D., Harris G. J., Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996 Dec;53(12):1293–1296. doi: 10.1001/archneur.1996.00550120105023. [DOI] [PubMed] [Google Scholar]
  8. Aylward E. H., Codori A. M., Rosenblatt A., Sherr M., Brandt J., Stine O. C., Barta P. E., Pearlson G. D., Ross C. A. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000 May;15(3):552–560. doi: 10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  9. Aylward E. H., Sparks B. F., Field K. M., Yallapragada V., Shpritz B. D., Rosenblatt A., Brandt J., Gourley L. M., Liang K., Zhou H. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004 Jul 13;63(1):66–72. doi: 10.1212/01.wnl.0000132965.14653.d1. [DOI] [PubMed] [Google Scholar]
  10. Chen M., Ona V. O., Li M., Ferrante R. J., Fink K. B., Zhu S., Bian J., Guo L., Farrell L. A., Hersch S. M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797–801. doi: 10.1038/77528. [DOI] [PubMed] [Google Scholar]
  11. DeKosky Steven T., Marek Kenneth. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003 Oct 31;302(5646):830–834. doi: 10.1126/science.1090349. [DOI] [PubMed] [Google Scholar]
  12. Dedeoglu Alpaslan, Kubilus James K., Yang Lichuan, Ferrante Kimberly L., Hersch Steven M., Beal M. Flint, Ferrante Robert J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003 Jun;85(6):1359–1367. doi: 10.1046/j.1471-4159.2003.01706.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Freeborough P. A., Fox N. C. Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr. 1998 Sep-Oct;22(5):838–843. doi: 10.1097/00004728-199809000-00031. [DOI] [PubMed] [Google Scholar]
  14. González-González M. C., Trujillo M. J., Rodríguez de Alba M., García-Hoyos M., Lorda-Sánchez I., Díaz-Recasens J., Ayuso C., Ramos C. Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat Diagn. 2003 Mar;23(3):232–234. doi: 10.1002/pd.570. [DOI] [PubMed] [Google Scholar]
  15. Grafton S. T., Mazziotta J. C., Pahl J. J., St George-Hyslop P., Haines J. L., Gusella J., Hoffman J. M., Baxter L. R., Phelps M. E. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol. 1992 Nov;49(11):1161–1167. doi: 10.1001/archneur.1992.00530350075022. [DOI] [PubMed] [Google Scholar]
  16. Graveland G. A., Williams R. S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science. 1985 Feb 15;227(4688):770–773. doi: 10.1126/science.3155875. [DOI] [PubMed] [Google Scholar]
  17. Gómez-Tortosa E., MacDonald M. E., Friend J. C., Taylor S. A., Weiler L. J., Cupples L. A., Srinidhi J., Gusella J. F., Bird E. D., Vonsattel J. P. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001 Jan;49(1):29–34. [PubMed] [Google Scholar]
  18. Halliday G. M., McRitchie D. A., Macdonald V., Double K. L., Trent R. J., McCusker E. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol. 1998 Dec;154(2):663–672. doi: 10.1006/exnr.1998.6919. [DOI] [PubMed] [Google Scholar]
  19. Harris G. J., Codori A. M., Lewis R. F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain. 1999 Sep;122(Pt 9):1667–1678. doi: 10.1093/brain/122.9.1667. [DOI] [PubMed] [Google Scholar]
  20. Hedreen J. C., Folstein S. E. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol. 1995 Jan;54(1):105–120. doi: 10.1097/00005072-199501000-00013. [DOI] [PubMed] [Google Scholar]
  21. Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001 Aug 14;57(3):397–404. doi: 10.1212/wnl.57.3.397. [DOI] [PubMed] [Google Scholar]
  22. Jenkins B. G., Rosas H. D., Chen Y. C., Makabe T., Myers R., MacDonald M., Rosen B. R., Beal M. F., Koroshetz W. J. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology. 1998 May;50(5):1357–1365. doi: 10.1212/wnl.50.5.1357. [DOI] [PubMed] [Google Scholar]
  23. Kassubek J., Juengling F. D., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):213–220. [PMC free article] [PubMed] [Google Scholar]
  24. Kirkwood S. C., Siemers E., Bond C., Conneally P. M., Christian J. C., Foroud T. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol. 2000 Jul;57(7):1040–1044. doi: 10.1001/archneur.57.7.1040. [DOI] [PubMed] [Google Scholar]
  25. Kirkwood S. C., Siemers E., Stout J. C., Hodes M. E., Conneally P. M., Christian J. C., Foroud T. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol. 1999 May;56(5):563–568. doi: 10.1001/archneur.56.5.563. [DOI] [PubMed] [Google Scholar]
  26. Lange H., Thörner G., Hopf A., Schröder K. F. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci. 1976 Aug;28(4):401–425. doi: 10.1016/0022-510x(76)90114-3. [DOI] [PubMed] [Google Scholar]
  27. Lasker A. G., Zee D. S. Ocular motor abnormalities in Huntington's disease. Vision Res. 1997 Dec;37(24):3639–3645. doi: 10.1016/S0042-6989(96)00169-1. [DOI] [PubMed] [Google Scholar]
  28. Lawrence A. D., Hodges J. R., Rosser A. E., Kershaw A., ffrench-Constant C., Rubinsztein D. C., Robbins T. W., Sahakian B. J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998 Jul;121(Pt 7):1329–1341. doi: 10.1093/brain/121.7.1329. [DOI] [PubMed] [Google Scholar]
  29. Mann D. M., Oliver R., Snowden J. S. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol. 1993;85(5):553–559. doi: 10.1007/BF00230496. [DOI] [PubMed] [Google Scholar]
  30. McCusker E., Richards F., Sillence D., Wilson M., Trent R. J. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. J Clin Neurosci. 2000 Jan;7(1):38–41. doi: 10.1054/jocn.1998.0151. [DOI] [PubMed] [Google Scholar]
  31. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B., Young A. B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5733–5737. doi: 10.1073/pnas.85.15.5733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Roos R. A., Pruyt J. F., de Vries J., Bots G. T. Neuronal distribution in the putamen in Huntington's disease. J Neurol Neurosurg Psychiatry. 1985 May;48(5):422–425. doi: 10.1136/jnnp.48.5.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rosas H. D., Liu A. K., Hersch S., Glessner M., Ferrante R. J., Salat D. H., van der Kouwe A., Jenkins B. G., Dale A. M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 2002 Mar 12;58(5):695–701. doi: 10.1212/wnl.58.5.695. [DOI] [PubMed] [Google Scholar]
  34. Rothwell J. C. Huntington's disease. A predictor of pathology. Nature. 2000 Feb 3;403(6769):495–496. doi: 10.1038/35000692. [DOI] [PubMed] [Google Scholar]
  35. Smith M. A., Brandt J., Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature. 2000 Feb 3;403(6769):544–549. doi: 10.1038/35000576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thieben M. J., Duggins A. J., Good C. D., Gomes L., Mahant N., Richards F., McCusker E., Frackowiak R. S. J. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain. 2002 Aug;125(Pt 8):1815–1828. doi: 10.1093/brain/awf179. [DOI] [PubMed] [Google Scholar]
  37. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D., Richardson E. P., Jr Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985 Nov;44(6):559–577. doi: 10.1097/00005072-198511000-00003. [DOI] [PubMed] [Google Scholar]
  38. de la Monte S. M., Vonsattel J. P., Richardson E. P., Jr Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol. 1988 Sep;47(5):516–525. doi: 10.1097/00005072-198809000-00003. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Web-only chart]
jnnpsyc_76_5_650__index.html (1.2KB, html)
jnnpsyc_76_5_650__1.pdf (30.7KB, pdf)

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES